Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1

Cancer Immunology Immunotherapy

Volumn 49, Issue 6, 2000, Pages 296-304

  Perico, Maria Elisa ^a   Mezzanzanica, Delia ^a   Luison, Elena ^a   Alberti, Paola ^a   Panza, Luigi ^b   Russo, Giovanni ^c   Canevari, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Glycoconjugates; Immunogenicity; Tumor associated antigen; Vaccine formulation

Indexed keywords

CANCER VACCINE; CARRIER PROTEIN; DIPHTHERIA TOXIN; GLYCOCONJUGATE; IMMUNOLOGICAL ADJUVANT; MPL; PHOSPHORYL LIPID A; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER PREVENTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033855365     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000113     Document Type: Article

References (39)

1. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients
2. In vitro mimicry CaMBrl tumor-associated antigen by synthetic oligosaccharides
3. Expression profile of saccharide epitope CaMBrl on normal and neoplastic tissue from dogs, cats, and rats: Implication for the development of human-derived cancer vaccines
4. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBrl expressed in normal and neoplastic epithelial cells of human mammary gland
5. Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBrl) which specifically binds to human mammary epithelial cells
6. Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-g)
7. Development and phase 1 clinical testing of a conjugate vaccine against menigococcus A and C
8. Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines
9. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: Serous and mucinous tumors exhibit distinctive patterns of expression
10. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
11. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid
12. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism
13. G(D3) vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines
14. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
15. Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: Towards the design of anticancer vaccines
16. Oligosaccharides related to tumor-associated antigens. Part 1*. Synthesis of the propyl glycoside of the trisaccharide α-L-Fucp-(1-2)-β-D-Galp-(l-3)-β-D-GalpNAc, component of a tumor antigen recognized by the antibody MBrl
17. Oligosaccharides related to tumor-associate antigens. Part 3*. Synthesis of the propyl glycosides of the trisaccharide β-D-Galp-(1-3)-β-D-GalpNAc-(1-3)-α-D-Galp and of the tetrasaccharide α-L-Fucp-(1-2)-β-D-Galp-(1-3)-β-D-GalpNAc-(1-3)-α-D-Galp, components of a tumor antigen recognized by the antibody MBrl
18. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines
19. Ganglioside vaccines with emphasis on GM2
20. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
21. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
22. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy
23. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant
24. Reactivity of a monoclonal antibody (MBr1) with normal and neoplastic breast epithelial cells in tissue sections and with metastatic breast cancer in effusions
25. Study of the expression and function of the tumor-associated antigen CaMBrl in small cell lung carcinomas
26. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes
27. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast
28. Prognostic significance of the CaMBrl antigen on breast carcinoma: Relevance of the type of recognised glycoconjugate
29. Carbohydrate antigens as targets for active specific immunotherapy
30. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
31. IgGl2a induced by IL-12-producing tumor cell vaccines but not IgGl induced by IL-4-vaccine are associated with the eradication of experimental metastases
32. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
33. Evaluation of monophosphoryl lipid a (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with M.P.L.
34. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
35. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients
36. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases
37. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen
38. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice
39. Selection of tumor antigens as targets for immune attack using immunohistochemistry 2. Blood group-related antigens